This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ANCN vs. NNVC, IBIO, TAOX, AEON, OBSV, AEZS, GRAY, NRBO, CPHI, and SPRBShould you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include NanoViricides (NNVC), iBio (IBIO), Synaptogenix (TAOX), AEON Biopharma (AEON), ObsEva (OBSV), Aeterna Zentaris (AEZS), Graybug Vision (GRAY), NeuroBo Pharmaceuticals (NRBO), China Pharma (CPHI), and Spruce Biosciences (SPRB). Anchiano Therapeutics vs. Its Competitors NanoViricides iBio Synaptogenix AEON Biopharma ObsEva Aeterna Zentaris Graybug Vision NeuroBo Pharmaceuticals China Pharma Spruce Biosciences NanoViricides (NYSE:NNVC) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation. Do insiders & institutionals hold more shares of NNVC or ANCN? 10.3% of NanoViricides shares are held by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are held by institutional investors. 4.6% of NanoViricides shares are held by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, NNVC or ANCN? NanoViricides has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Is NNVC or ANCN more profitable? Anchiano Therapeutics' return on equity of 36.08% beat NanoViricides' return on equity.Company Net Margins Return on Equity Return on Assets NanoViricidesN/A -87.90% -78.69% Anchiano Therapeutics N/A 36.08%27.40% Which has stronger earnings & valuation, NNVC or ANCN? NanoViricides is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanoViricidesN/AN/A-$8.29M-$0.70-2.27Anchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.28 Does the media prefer NNVC or ANCN? In the previous week, NanoViricides' average media sentiment score of 0.50 beat Anchiano Therapeutics' score of 0.00 indicating that NanoViricides is being referred to more favorably in the media. Company Overall Sentiment NanoViricides Positive Anchiano Therapeutics Neutral SummaryNanoViricides beats Anchiano Therapeutics on 5 of the 9 factors compared between the two stocks. Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANCN vs. The Competition Export to ExcelMetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.27M$782.30M$5.56B$9.47BDividend YieldN/A4.84%4.31%4.17%P/E Ratio6.531.3029.3723.99Price / SalesN/A25.47444.7496.71Price / CashN/A19.5635.8458.51Price / Book0.496.598.085.58Net Income-$27.12M-$4.20M$3.26B$265.35M Anchiano Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANCNAnchiano TherapeuticsN/A$0.98+1.0%N/A-6.7%$7.27MN/A6.5316Gap UpNNVCNanoViricides0.497 of 5 stars$1.70flatN/A-22.8%$27.32MN/A-2.3620IBIOiBio1.1857 of 5 stars$0.69-2.8%$5.00+624.7%-68.5%$11.40M$375K0.00100TAOXSynaptogenixN/A$6.86+5.2%N/AN/A$9.06MN/A0.004AEONAEON Biopharma3.38 of 5 stars$0.78-1.4%$360.00+46,172.5%-98.9%$8.80MN/A4.325Upcoming EarningsGap UpOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050AEZSAeterna ZentarisN/A$3.90-1.5%N/A-27.1%$6.99M$2.37M-0.2620Upcoming EarningsGap DownGRAYGraybug VisionN/A$3.80+3.0%N/A-28.6%$5.97MN/A-2.2027High Trading VolumeNRBONeuroBo PharmaceuticalsN/A$0.66-5.9%N/A-84.5%$5.72MN/A0.0010Upcoming EarningsHigh Trading VolumeCPHIChina PharmaN/A$1.74-4.9%N/A-90.9%$5.68M$4.30M0.00250SPRBSpruce Biosciences2.4941 of 5 stars$0.12+10.0%$1.75+1,373.1%-99.6%$5.02M$4.91M-0.1320News CoverageUpcoming EarningsGap Up Related Companies and Tools Related Companies NNVC Alternatives IBIO Alternatives TAOX Alternatives AEON Alternatives OBSV Alternatives AEZS Alternatives GRAY Alternatives NRBO Alternatives CPHI Alternatives SPRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANCN) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
